Andrew Newland on ANGLE's new Myriad collaboration

ANGLE PLC has announced a significant joint development partnership with Myriad Genetics, a major diagnostics company generating nearly $1 billion in annual revenue. This collaboration focuses on adapting Myriad's existing cancer tests, currently reliant on tissue biopsies, to utilize circulating tumor cells recovered by ANGLE's Parsortix system from blood samples. The agreement provides ANGLE with immediate revenue as Myriad covers development costs, while also creating substantial future commercial opportunities through potential widespread adoption of Parsortix consumables for minimally invasive, repeatable cancer testing. This partnership validates ANGLE's technology and could accelerate a broader industry shift towards blood-based diagnostics, enabling earlier detection and continuous patient monitoring.

Analysis

ANGLE PLC has secured a strategically significant joint development partnership with Myriad Genetics, a major diagnostics company with approximately $1 billion in annual revenue. This collaboration is a critical validation of ANGLE's business model, which aims to embed its Parsortix system within the workflows of large diagnostic firms. The agreement will focus on adapting Myriad's existing cancer tests, which are primarily based on invasive tissue biopsies, to utilize circulating tumor cells harvested from blood by the Parsortix system. Financially, the deal is structured favorably for ANGLE, as Myriad will cover all development costs, providing near-term revenue and a clear path to commercialization without significant capital outlay from ANGLE. The long-term value proposition is substantial, as successful clinical adoption by Myriad could generate significant recurring revenue from the sale of Parsortix cassettes for potentially hundreds of thousands of tests annually. This partnership represents the first major diagnostic company to formally collaborate with ANGLE, potentially signaling a broader industry shift towards minimally invasive liquid biopsies for earlier cancer detection and repeat patient monitoring.

Key Decisions for Investors

• This partnership materially de-risks ANGLE's commercialization path and provides a significant potential catalyst; investors should monitor key milestones including the publication of trial results and announcements of further development contracts with Myriad.
• For ANGLE, the deal structure minimizes near-term cash burn while creating a substantial long-term revenue opportunity, improving the company's risk/reward profile pending successful clinical outcomes.
• A successful outcome with Myriad could attract other major diagnostic players, so investors should consider this a key validation point and watch for any signs of wider adoption of the Parsortix platform.
• For Myriad Genetics, this collaboration represents a relatively low-cost strategic investment to expand its testing capabilities into the liquid biopsy market, potentially opening new avenues for growth in patient monitoring and earlier-stage diagnostics.